Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Neuralstem: Previewing Upcoming Important Events and Some Thoughts on the StemCell Patent Infringement Lawsuit (CUR, $3.62 Buy, August 26, 2014)

Key Points

The phase 2 trial of NSI-566 in 15 ALS patients has completed enrollment (surgeries) and final topline data could…
Read more…

Neuralstem: Phase 1b Results for NSI-189 are Very Encouraging but It Is Early Days (CUR, Buy, $4.38, For paid subscribers)

Investment Thesis on Neuralstem

I continue with my long standing buy on Neuralstem that is almost entirely based on the potential…
Read more…

Neuralstem: Encouraging Phase 1b Data on NSI-189 (CUR, Buy, $4.35, Free content)

On June 17 at the American Society of Clinical Psychopharmacology Neuralstem reported phase 1b data for its small molecule drug…
Read more…

Neuralstem: An In-Depth Look at NSI-189, A Novel Small Molecule Drug Being Studied in Major Depressive Disorder (CUR, Buy, $3.60, For Paid Subscribers)

Investment Thesis

My recommendation of Neuralstem (CUR) has been based primarily on the potential for its neural stem cells NSI-566 in…
Read more…